-
by Shopify API
Save Our Sons Duchenne Foundation (SOSDF) thanks all Queensland families and young people who have participated in our recent consult...
-
by Shopify API
Are you on the Australian Neuromuscular Disease Registry (ANMDR)?
With an increasing number of pharmaceutical companies interested to run clinic...
-
by Shopify API
Sarepta Therapeutics has shared an update about themulti-ascending dose clinical trial of SRP-5051 for patients with Duchennemuscular dystrophy...
-
by Shopify API
Sarepta Therapeutics has, last week, announced thatthey will be hosting a webcast and conference call to present resultsfrom the 30 mg/kg arm o...
-
by Shopify API
Dear members of the Duchenne and Becker community.
You may recall that just prior to Christmas we advised of a community consultation process...
-
by Shopify API
You may be aware that the National Disability Insurance Scheme (NDIS) is currently undertaking a consultation process with NDIS participants an...
-
by Shopify API
Yesterday, Save Our Sons Duchenne Foundation hosted an NDIS Information Session.
The aim of the session was for families to become familiar wi...
-
by Shopify API
Today, Save Our Sons Duchenne Foundation hosted a Carriers Information Session.
The aim of the session was to provide an overview and gain a b...
-
by Shopify API
SOSDF would like to thank all parents and carers who recently participated in our consultation process reviewing health and hospital services i...
-
by Shopify API
Murdoch Children’s Research Institute (MCRI) - Royal Children’s Hospital Melbourne
Funding towards the position of Neuromuscular Clinical Tria...
-
by Shopify API
Catabasis Pharmaceuticals has announced the end of the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy. Edasalonexent ...
-
by Shopify API
Save Our Sons have lodged a comprehensive submission to this most important Parliamentary Inquiry.
As the peak body representing the Duchenne a...
Use left/right arrows to navigate the slideshow or swipe left/right if using a mobile device
